$AQST Inverted hammer on the daily. Looks like a breakout could be tomorrow. What is the bear case here? Used to be dilution, but that was disproved after the financing deal. A clerical issue fix should help get Libervant approved, so I don't think bears can bank on FDA rejection. The company continues to grow revenue and has MANY catalysts upcoming. Short float is still 8%. What are the Bears hoping for?
  • 4
4 Likes